EU nod for Samsung Bioepis’ Remicade Biosimilar

Samsung Bioepis’ biosimilar of J&J’s blockbuster anti-inflammatory, infliximab, has won regulatory approval in Europe, which could potentially expand access to anti-TNF therapies in the region. Like its reference product, Flixabi has been cleared by the EU Commission for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. The decision

Continue Reading